M&A activity snapshot
Lab M&A is dominated by two national buyers. Quest Diagnostics (NYSE: DGX) and Labcorp (NYSE: LH) have completed over 15 acquisitions combined since beginning of Q1 2024, per Hyde Park Capital's mid-2025 review. The same report sizes the market at $99.7 billion of revenue in 2024, projected to reach $122.5 billion by 2029.
The base of possible targets is large and mixed. CMS says CLIA covers approximately 320,000 laboratory entities, while Hyde Park cites over 250,000 CLIA-certified labs. The counts differ by scope, and both include physician-office and small sites, not just independent reference labs.
Hospital outreach businesses are the most active deal type. Labcorp agreed to buy outreach assets from Community Health Systems for $195 million covering 13 states. It also agreed to buy clinical lab assets from Empire City Laboratories for an initial $165 million. Quest completed its previously announced acquisition of select assets of University Hospitals in Ohio in January 2025.
Who is buying
The national labs buy outreach books, regional labs, and specialty assets. Labcorp spent $324 million in cash on acquisitions in the first nine months of 2025. It aims to derive 1.5% to 2.5% of annual growth from acquisitions. Quest names Laboratory Corporation of America Holdings as its largest commercial lab competitor.
Health systems are also partners, not only sellers. Quest and Corewell Health formed a Michigan lab joint venture with equity ownership shared 51% by Quest and 49% by Corewell Health. Quest will also manage all of Corewell Health's 21 inpatient and outpatient hospital labs.
Private equity is the other bidder. Hyde Park reports independent laboratories are still highly sought after by both strategics looking to add further scale and density, as well as private equity seeking platforms or add-ons. Imaging centers are a related but separate category and are not covered on this page.
What buyers look for
Payer mix is the first screen, because Medicare lab rates are unstable. Under PAMA, the first round of rate-setting led to nearly $4 billion in cuts to labs running the most commonly ordered tests. At Quest, the Medicare Clinical Laboratory Fee Schedule accounted for 8% of 2025 consolidated net revenue.
Test volume and route density come next. National labs buy outreach books to add physician clients and specimen volume to existing lab capacity. Quest says it serves approximately half the hospitals in the United States each year. Hyde Park notes that national-lab deals for hospital assets often include service arrangements tied to the acquisition.
Specialty capability is the third. Hyde Park notes that niche testing labs may command higher premiums due to their more niche offerings. Regulatory risk around lab-developed tests eased in 2025 after a federal court vacated the agency's rule on laboratory-developed tests (LDTs).
What makes a strong company
Labs that draw strong buyer interest tend to show:
- Current CLIA certification at the right complexity level, with clean survey and proficiency-testing history.
- A payer mix weighted to commercial contracts, with limited exposure to Medicare fee-schedule cuts.
- A dense client base of physician practices in one region, which fits a national lab's courier routes.
- Specialty or esoteric tests that national labs do not already run at scale.
- Billing and coding records that hold up to payer audits, since lab billing draws frequent scrutiny.
Valuation and deal structure
Private lab deal multiples are rarely disclosed. Most outreach deals are asset purchases at a stated price, such as Labcorp's $195 million CHS purchase, without a published EBITDA multiple. Quest did not disclose terms for University Hospitals: financial terms were not disclosed.
Public companies give an upper reference point, not a private-deal benchmark. For Labcorp, Quest, and Sonic, Hyde Park's comparables show a median EV/LTM EBITDA of 11.0x as of June 23, 2025. Smaller private labs typically price below scaled public companies, but no free source reviewed here publishes a private-lab median.
Joint ventures are a growing alternative to outright sales. In the Corewell deal, the health system kept a 49% stake. Labcorp's CEO said in October 2025 that the hospital pipeline does remain strong.
Outlook
PAMA remains the main swing factor for the next 12-24 months. The Consolidated Appropriations Act, 2026 included a one-year delay of pending Medicare Clinical Laboratory Fee Schedule (CLFS) cuts, and updated the private-payer data used for 2027 rates from 2019 to 2025. As of February 2026, Congress has intervened on a bipartisan basis seven times to delay reporting and cuts.
Outreach consolidation looks set to continue. Health systems keep selling or partnering on non-emergent testing, as Parkview did with Labcorp, while keeping labs inside its hospitals for acute care. Independent labs with commercial payer mix and specialty menus should keep drawing both national strategics and PE.
Own a clinical lab and want a baseline before you talk to a buyer? Run the valuation tool. Back to Healthcare Services M&A. See also: how independent sponsors build deal flow.